Skip to Main Content

Hello, everyone, and how are you today? A shiny sun is warming the chilly Pharmalot campus this morning, where the officials mascots are happily snoozing. As for us, we are staring at an intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing…

Prime Therapeutics is the latest pharmacy benefits manager to refuse to cover Auvi-Q, the relaunched rival to EpiPen, over its $4,500 list price. “Consumers and payers are simply being taken advantage of when products are 100 percent to 1,500 perent more expensive than comparable products,” says Prime chief financial officer Alec Mahmood. He insisted PBMs and payers are “a critical counterweight to this egregious behavior.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED